Savara Secures $75M in Additional Debt Funding Upon FDA Approval of MOLBREEVI

Savara Inc., a biopharmaceutical company, has amended its loan agreement with Hercules Capital, allowing for up to $75 million in additional debt funding upon FDA approval of MOLBREEVI, a therapy for autoimmune pulmonary alveolar proteinosis. The amended agreement strengthens Savara's balance sheet and liquidity, enabling the company to support potential launch activities with non-dilutive capital. The FDA resubmitted the MOLBREEVI Biologics License Application in December 2025, with potential approval in 3Q 2026.